News

Minimal Glucocorticoid Regimen Shows Similar Efficacy, Fewer Adverse Events than Standard Treatments, Study Reports

Patients with ANCA-associated vasculitis (AAV) who receive a minimal glucocorticoid treatment along with Rituxan (rituximab) and cyclophosphamide show similar improvement as those given standard glucocorticoid regimens, but have lower glucocorticoid-associated adverse events, a study shows. The study, “A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis,” was published…

Atypical ANCAs Do Not Contribute to Vessel Inflammation in Patients with Eye Disease, Study Suggests

The presence of atypical ANCA antibodies in people with underlying eye inflammatory disease is not linked to severe vessel inflammation or worse outcomes, a small study reports. The study, “Atypical Perinuclear Anti-Neutrophil Cytoplasmic Antibodies in Ocular Inflammatory Diseases,” was published in the journal Ocular Immunology and Inflammation. ANCA-associated…

ANCA Vasculitis Maintenance Therapy Imuran Causes Allergic Reaction in Kidneys, Case Report Shows

A patient taking Imuran (azathioprine) to treat his ANCA-associated vasculitis experienced an acute allergic reaction to the therapy which manifested as a kidney inflammation. Researchers should be aware of this complication to promptly distinguish disease relapse from acute reactions to the medicine. The case report, “Azathioprine-induced interstitial nephritis…